Lessons From Galvus: Novartis Teams Up With India’s Lupin To Market COPD Drug Onbrez
This article was originally published in PharmAsia News
Novartis will compete against market leader Cipla to make a dent in the emerging Indian COPD space.
You may also be interested in...
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.